Developer docs
API playgroundTry for free, no card

Search company profiles

SMA Europe

Full company profile

uuid0033d5f

Namestring
SMA Europe
Legal namestring
SMA Europe e. V.
Websiteurl
sma-europe.eu
Company typeenum
Private
Founded yearint
2004
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersFreiburg, Germany
HQ citystring
Freiburg
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease advocacy, patient umbrella organization, SMA research funding, clinical trials finder, patient advocate training
NAICS code2 codes
  • Social Advocacy Organizations8133
  • Business Associations813910
SIC code1 code
  • Services-Membership Organizations8600
Product category
Rare Disease Patient Advocacy and Research Funding
Revenue model4 records
1Membership Fees
TypeSubscription Recurring
Description

SMA Europe receives annual membership fees from its member patient organisations across Europe.

sma-europe.eu
2Donations and Grants
TypeOthers
Description

Voluntary donations from member organisations and grants from other non-profit organisations support the organisation's activities.

sma-europe.eu
3Corporate Funding
TypeLicensing Royalties
Description

Funding from health sector corporates including pharmaceutical companies, with all partnerships established under a code of practice ensuring shared interest, transparency, trust, and mutual benefit.

sma-europe.eu
4Event Fees
TypeProfessional Services
Description

Registration fees collected from the International Clinical Care Symposium and other educational events.

sma-europe.eu
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Others, Marketing or Sales, Operations, Technology or R&D
Pricing details2 tiers
1Free membership for national SMA patient organisations
ModelFreemiumBilling cadenceAnnual
Notes

Membership is open to national patient organisations led by people living with SMA and their families at no cost.

sma-europe.eu
2Clinical Care Symposium registration fees
ModelSubscriptionBilling cadenceMulti-year contract
Notes

On-site: Student/PhD €X, Clinician/Healthcare Professional/Researcher €X, Industry Representative €X. Online: Student/PhD €X, Clinician/Healthcare Professional/Researcher €X, Industry Representative €X.

sma-europe.eu
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Brand1 of 3 records shown
1OdySMA
Description

A quest initiative by SMA Europe to highlight challenges in access to medicines and care, featuring an atlas that shows evidence-based gaps and challenges across Europe.

sma-europe.eu
+2 more records
Core offering1 text field

SMA Europe is a non-profit umbrella organisation that coordinates 30 national SMA patient organisations across 28 European countries, delivering biennial research funding calls, evidence-based patient advocacy at European regulatory bodies, patient experience surveys (EUPESMA), clinical trial information, patient advocate training (SMAcademy), and the International Clinical Care Symposium. Its core outputs are research grants, advocacy representation, educational programs, and information platforms for the SMA community.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 98% of survey respondents indicated there is a need for new clinical trials in SMA
+1 more record
Product overview1 text field

SMA Europe is a non-profit umbrella organization that operates as a platform of interconnected services focused on research funding, patient advocacy, access to treatments, and community support for spinal muscular atrophy (SMA). The organization manages multiple programs including the Call for Research Proposals (funding €6+ million since 2008), OdySMA Access Hub (access to medicines advocacy), EUPESMA patient survey series, Clinical Trials Hub, SMA Daily Life Study (patient-relevant outcomes research), SMAcademy (patient advocate training), and the International Clinical Care Symposium. The portfolio spans research funding, patient experience data collection, treatment access advocacy, educational programs, and community convening. No unified software product or platform is offered; rather, the organization provides services, programs, and information resources.

Product and service7 records
1OdySMA Access Hub
CategoryPatient Access Advocacy Platform
Description

Community mobilisation initiative and evidence-based atlas highlighting challenges and gaps in access to SMA medicines and care across Europe, designed to ensure no one is left behind.

2EUPESMA Patient Experience Survey Series
CategoryResearch/Survey Platform
Description

Pan-European survey series (EUPESMA-2025, 2023, 2021, 2019, and first survey) collecting longitudinal data on SMA patient experiences, expectations, treatment access, and clinical trial interest, published under ISSN 3134-6626.

3Clinical Trials Finder
CategoryInformation Platform
Description

Searchable web-based platform providing the SMA community with information about SMA clinical trials available across Europe.

4SMA Daily Life Study
CategoryResearch Program
Description

Longitudinal research study following individuals living with SMA over time to understand how SMA impacts daily living across areas such as fatigue, pain, and mental health, in partnership with Tilburg University.

5SMA Patient Advocate Training (SMAcademy)
CategoryEducational Program
Description

Five-module self-paced e-learning programme equipping SMA patient advocates with knowledge and skills, culminating in an SMA Patient Advocate Training Certificate issued by SMA Europe.

6Call for Research Proposals
CategoryFunding Program
Description

Biennial funding programme supporting high-quality scientific projects aimed at advancing understanding of SMA and improving outcomes for people living with SMA; €6,091,034 funded since 2008 across 13 calls.

7International Clinical Care Symposium on SMA
CategoryConference / Educational Event
Description

Biennial international symposium bringing together clinicians, researchers, and patient advocates to explore innovative solutions in SMA care; the 2nd edition will be held in Prague on 4-5 March 2027 with a focus on musculoskeletal care.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

US-based SMA patient organisation collaborating on transversal issues to improve the lives of people with SMA and their families.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Indian SMA patient organisation partner working on shared goals related to SMA awareness and advocacy.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

European Patients' Academy on Therapeutic Innovation - collaboration on patient education and engagement in medicines research.

4EURO-NMD
Strategic tierCoreTypeStrategic or Co-development Partner
Description

European Reference Network for Rare Neuromuscular Diseases - collaboration on neuromuscular disease standards and care.

sma-europe.eu
Strategic tierCoreTypeStrategic or Co-development Partner
Description

EMA is represented at SMA Europe, with the organisation participating in EMA activities to elevate the patient voice in regulatory decisions.

6European Neuromuscular Centre (ENMC)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

International research organisation focused on neuromuscular diseases, collaborating on workshops and research initiatives.

sma-europe.eu
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Rare Diseases Europe - umbrella organisation for rare disease patient organisations across Europe, collaborating on policy and advocacy.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Online news platform dedicated to SMA news and updates, collaborating on information dissemination.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Digital magazine covering rare disease stories and issues, collaborating on awareness and communication.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

International network for neuromuscular diseases providing patient registry and research coordination support.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic partnership for the SMA Daily Life Study, collaborating on research into patient-relevant outcomes such as fatigue, pain, and mental health.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

International neuromuscular disease research network, listed as a core SMA Europe partner for patient registry and research coordination. Highly comparable in patient-relevant research focus, although Treat-NMD emphasizes research infrastructure rather than direct advocacy.

TypeDirect peer
Description

French neuromuscular disease patient organization and major co-funder of SMA Europe's 13th Call for Research Proposals. Operates a similar model combining research funding, patient advocacy, and disease-specific programs in the neuromuscular space.

TypeBroad incumbent
Description

Pan-European umbrella of patient organizations across all disease areas. Operates with a similar member-organization model and policy advocacy mandate but at a wider thematic scope than SMA Europe.

TypeDirect peer
Description

Pan-European umbrella of rare disease patient organizations, listed by SMA Europe as a core partner. Highly comparable in structure and operating model, though EURORDIS spans all rare diseases rather than focusing on SMA alone.

TypeDirect peer
Description

Indian SMA patient organization listed as a partner of SMA Europe, focused on SMA awareness and advocacy in India. Directly comparable disease focus but operating in a different geographic market.

TypeDirect peer
Description

Leading US-based SMA patient organization that funds research and runs the Annual SMA Conference. Named as a core strategic partner of SMA Europe for collaboration on transversal SMA issues — directly comparable mission and program mix.

TypeBroad incumbent
Description

US-based umbrella for rare disease patient organizations with structural and operational similarities to SMA Europe, but operating across the full rare disease spectrum and on a larger scale.

TypeBroad incumbent
Description

Large US neuromuscular disease advocacy and research funder with overlapping SMA-relevant programs but a much broader disease mandate and substantially larger budget. Comparable in mission, much larger in scale and scope.

TypeDirect peer
Description

US-based patient organization for Duchenne muscular dystrophy with a similar portfolio of research funding, advocacy, and clinical education programs. Closely mirrors SMA Europe's structure and program mix in a neighboring neuromuscular disease.

10EURO-NMD – European Reference Network for Rare Neuromuscular Diseases
TypeDirect peer
Description

European Reference Network collaborating with SMA Europe on neuromuscular disease standards and care. Comparable in focus on neuromuscular disease coordination, though EURO-NMD is a clinical reference network rather than a patient membership body.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SMA Europe

Rare Disease Patient Advocacy and Research Fundingsma-europe.eu

SMA Europe firmographics

Firmographics
Name
SMA Europe
Legal name
SMA Europe e. V.
Website
https://sma-europe.eu
Company type
Private
Founded year
2004
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Where SMA Europe is headquartered

Location

Headquarters

HQ city
Freiburg
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

SMA Europe business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Personnel, Others, Marketing or Sales, Operations, Technology or R&D

Revenue model

  1. Membership Fees: SMA Europe receives annual membership fees from its member patient organisations across Europe.
  2. Donations and Grants: Voluntary donations from member organisations and grants from other non-profit organisations support the organisation's activities.
  3. Corporate Funding: Funding from health sector corporates including pharmaceutical companies, with all partnerships established under a code of practice ensuring shared interest, transparency, trust, and mutual benefit.
  4. Event Fees: Registration fees collected from the International Clinical Care Symposium and other educational events.

Pricing tiers

ModelBillingPrice
FreemiumAnnualFree membership for national SMA patient organisations
SubscriptionMulti-year contractClinical Care Symposium registration fees

Distribution channels5 records

Marketing channels9 records

SMA Europe product offering

Product offering

Core offering

SMA Europe is a non-profit umbrella organisation that coordinates 30 national SMA patient organisations across 28 European countries, delivering biennial research funding calls, evidence-based patient advocacy at European regulatory bodies, patient experience surveys (EUPESMA), clinical trial information, patient advocate training (SMAcademy), and the International Clinical Care Symposium. Its core outputs are research grants, advocacy representation, educational programs, and information platforms for the SMA community.

Product overview

SMA Europe is a non-profit umbrella organization that operates as a platform of interconnected services focused on research funding, patient advocacy, access to treatments, and community support for spinal muscular atrophy (SMA). The organization manages multiple programs including the Call for Research Proposals (funding €6+ million since 2008), OdySMA Access Hub (access to medicines advocacy), EUPESMA patient survey series, Clinical Trials Hub, SMA Daily Life Study (patient-relevant outcomes research), SMAcademy (patient advocate training), and the International Clinical Care Symposium. The portfolio spans research funding, patient experience data collection, treatment access advocacy, educational programs, and community convening. No unified software product or platform is offered; rather, the organization provides services, programs, and information resources.

Differentiator

Problem solved

Functional benefit

Brands

  • OdySMA: A quest initiative by SMA Europe to highlight challenges in access to medicines and care, featuring an atlas that shows evidence-based gaps and challenges across Europe.
  • SMAcademy
  • EUPESMA

Products and services

  • OdySMA Access Hub Community mobilisation initiative and evidence-based atlas highlighting challenges and gaps in access to SMA medicines and care across Europe, designed to ensure no one is left behind.
  • EUPESMA Patient Experience Survey Series Pan-European survey series (EUPESMA-2025, 2023, 2021, 2019, and first survey) collecting longitudinal data on SMA patient experiences, expectations, treatment access, and clinical trial interest, published under ISSN 3134-6626.
  • Clinical Trials Finder Searchable web-based platform providing the SMA community with information about SMA clinical trials available across Europe.
  • SMA Daily Life Study Longitudinal research study following individuals living with SMA over time to understand how SMA impacts daily living across areas such as fatigue, pain, and mental health, in partnership with Tilburg University.
  • SMA Patient Advocate Training (SMAcademy) Five-module self-paced e-learning programme equipping SMA patient advocates with knowledge and skills, culminating in an SMA Patient Advocate Training Certificate issued by SMA Europe.
  • Call for Research Proposals Biennial funding programme supporting high-quality scientific projects aimed at advancing understanding of SMA and improving outcomes for people living with SMA; €6,091,034 funded since 2008 across 13 calls.
  • International Clinical Care Symposium on SMA Biennial international symposium bringing together clinicians, researchers, and patient advocates to explore innovative solutions in SMA care; the 2nd edition will be held in Prague on 4-5 March 2027 with a focus on musculoskeletal care.

Quantifiable outcome

  • 98% of survey respondents indicated there is a need for new clinical trials in SMA
  • +1 more outcomes

Companies that use SMA Europe

Customer profile

Segments3 records

Ideal customer profiles4 records

SMA Europe technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

SMA Europe partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core and minor.

  • Cure SMAcoreStrategic or Co-development PartnerUS-based SMA patient organisation collaborating on transversal issues to improve the lives of people with SMA and their families.
  • CureSMA IndiaminorStrategic or Co-development PartnerIndian SMA patient organisation partner working on shared goals related to SMA awareness and advocacy.
  • EUPATIcoreStrategic or Co-development PartnerEuropean Patients' Academy on Therapeutic Innovation - collaboration on patient education and engagement in medicines research.
  • EURO-NMDcoreStrategic or Co-development PartnerEuropean Reference Network for Rare Neuromuscular Diseases - collaboration on neuromuscular disease standards and care.
  • European Medicines AgencycoreStrategic or Co-development PartnerEMA is represented at SMA Europe, with the organisation participating in EMA activities to elevate the patient voice in regulatory decisions.
  • European Neuromuscular Centre (ENMC)coreStrategic or Co-development PartnerInternational research organisation focused on neuromuscular diseases, collaborating on workshops and research initiatives.
  • EURORDIScoreStrategic or Co-development PartnerRare Diseases Europe - umbrella organisation for rare disease patient organisations across Europe, collaborating on policy and advocacy.
  • SMA News TodayminorStrategic or Co-development PartnerOnline news platform dedicated to SMA news and updates, collaborating on information dissemination.
  • Rare Revolution MagazineminorStrategic or Co-development PartnerDigital magazine covering rare disease stories and issues, collaborating on awareness and communication.
  • Treat-NMDcoreStrategic or Co-development PartnerInternational network for neuromuscular diseases providing patient registry and research coordination support.
  • Tilburg UniversitycoreStrategic or Co-development PartnerAcademic partnership for the SMA Daily Life Study, collaborating on research into patient-relevant outcomes such as fatigue, pain, and mental health.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

SMA Europe competitors and assessment

Company assessment

Direct peers

  • Treat-NMD: International neuromuscular disease research network, listed as a core SMA Europe partner for patient registry and research coordination. Highly comparable in patient-relevant research focus, although Treat-NMD emphasizes research infrastructure rather than direct advocacy.
  • AFM-Téléthon: French neuromuscular disease patient organization and major co-funder of SMA Europe's 13th Call for Research Proposals. Operates a similar model combining research funding, patient advocacy, and disease-specific programs in the neuromuscular space.
  • EURORDIS – Rare Diseases Europe: Pan-European umbrella of rare disease patient organizations, listed by SMA Europe as a core partner. Highly comparable in structure and operating model, though EURORDIS spans all rare diseases rather than focusing on SMA alone.
  • CureSMA India: Indian SMA patient organization listed as a partner of SMA Europe, focused on SMA awareness and advocacy in India. Directly comparable disease focus but operating in a different geographic market.
  • Cure SMA: Leading US-based SMA patient organization that funds research and runs the Annual SMA Conference. Named as a core strategic partner of SMA Europe for collaboration on transversal SMA issues — directly comparable mission and program mix.
  • Parent Project Muscular Dystrophy (PPMD): US-based patient organization for Duchenne muscular dystrophy with a similar portfolio of research funding, advocacy, and clinical education programs. Closely mirrors SMA Europe's structure and program mix in a neighboring neuromuscular disease.
  • EURO-NMD – European Reference Network for Rare Neuromuscular Diseases: European Reference Network collaborating with SMA Europe on neuromuscular disease standards and care. Comparable in focus on neuromuscular disease coordination, though EURO-NMD is a clinical reference network rather than a patient membership body.

Broad incumbents

  • European Patients' Forum (EPF): Pan-European umbrella of patient organizations across all disease areas. Operates with a similar member-organization model and policy advocacy mandate but at a wider thematic scope than SMA Europe.
  • NORD – National Organization for Rare Disorders: US-based umbrella for rare disease patient organizations with structural and operational similarities to SMA Europe, but operating across the full rare disease spectrum and on a larger scale.
  • Muscular Dystrophy Association (MDA): Large US neuromuscular disease advocacy and research funder with overlapping SMA-relevant programs but a much broader disease mandate and substantially larger budget. Comparable in mission, much larger in scale and scope.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

SMA Europe social profiles

Digital presence

SMA Europe financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SMA Europe leadership team

Management profile

Number of profiles

Profiles17 records

SMA Europe funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SMA Europe M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SMA Europe

What does SMA Europe do?

SMA Europe is a non-profit umbrella organisation that coordinates 30 national SMA patient organisations across 28 European countries, delivering biennial research funding calls, evidence-based patient advocacy at European regulatory bodies, patient experience surveys (EUPESMA), clinical trial information, patient advocate training (SMAcademy), and the International Clinical Care Symposium. Its core outputs are research grants, advocacy representation, educational programs, and information platforms for the SMA community.

Is SMA Europe a public or private company?

SMA Europe is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was SMA Europe founded?

SMA Europe was founded in 2004. It employs 11 to 50 people.

Where is SMA Europe based?

SMA Europe is headquartered in Freiburg, Germany, in the Europe region.

How does SMA Europe make money?

Four revenue lines are on record. Membership Fees are the primary driver. The others are donations and Grants, corporate Funding and event Fees.

Who are SMA Europe's main competitors?

Direct peers on record are Treat-NMD, AFM-Téléthon, EURORDIS – Rare Diseases Europe, CureSMA India, Cure SMA, Parent Project Muscular Dystrophy (PPMD) and EURO-NMD – European Reference Network for Rare Neuromuscular Diseases. Broad incumbents are European Patients' Forum (EPF), NORD – National Organization for Rare Disorders and Muscular Dystrophy Association (MDA).

Does SMA Europe have an API?

No public API is recorded for SMA Europe.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals